A Virtual Network to Investigate the Effectiveness of COVID-19 and influenza vaccines and evaluate the burden and epidemiology of respiratory viruses Epidemiology and Incidence of Influenza and Other Acute Respiratory Illnesses

The Centers for Disease Control and Prevention (CDC), Office of the Director/Influenza Division National Center for Immunization and Respiratory Diseases hereby announces its intent to sole source, firm fixed price purchase order to Kaiser Permanente Northern California, Bernard J. Tyson School of Medicine, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612. Kaiser Permanente Northern California, Bernard J Tyson School of Medicine is the only vendor who can provide the critical and urgent public health priorities regarding respiratory viruses. The Centers for Disease Control and Prevention (CDC) requires a network of healthcare systems with timely access to integrated electronic health record (EHR) data, that can identify children and adults with SARS-CoV-2, influenza, and RSV testing and infection, including in urgent care (UC), emergency department (ED), inpatient, and intensive care unit (ICU) settings, and collect details on vaccination status, symptoms, severity, duration, treatments, and outcomes to address current and future information gaps. This services provided will include: 1) assessing COVID-19, influenza and RSV testing frequency, test type, and test results across age groups, care settings, disease severity, and population subgroups; 2) assessing COVID-19 and influenza VE across age groups, care settings, disease severity, and population subgroups (e.g., people with immunocompromising conditions); when RSV vaccines are available, evaluating RSV VE in eligible persons; 3) assessing COVID-19, influenza, and RSV (when available) vaccination coverage by dose number and product type; 4) describing the epidemiology and clinical characteristics of COVID-19, influenza, and RSV across age groups, care settings, disease severity, and population subgroups; 5) describing the trajectory of care for individuals with COVID-19, influenza, and RSV including severe outcomes (e.g., ICU admission, mechanical ventilation, in-hospital death) and post-acute sequelae (e.g., new-onset clinical diagnoses); and 6) assessing use of therapies for the treatment and prophylaxis for COVID-19, influenza, and RSV, and impact of these therapies in preventing illness and/or attenuating disease severity. This contract action is for services which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1(ii) . The North American Industry Classification System(NAICs) code for this procurement is 541380 – Testing Laboratories Interested vendors that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Specialist by May 4, 2023. The Contract Specialist will not respond to verbal requests. All requests must be in writing. This is not a request for competitive quotations: however, the Government will review any/all product, capabilities, and pricing information submitted prior to the closure of this notice. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.